Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 4/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 13/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117936 | 0.84 | AVPR2 (0.43) | AVPR1AAVPR2 | |
| SCHEMBL5117311 | 0.84 | AVPR2 (0.43) | AVPR1AAVPR2 | |
| SCHEMBL5119243 | 0.81 | AVPR2 (0.46) | AVPR1AAVPR2OXTR | |
| SCHEMBL5143793 | 0.81 | AVPR2 (0.46) | AVPR1AAVPR2OXTR | |
| SCHEMBL5111220 | 0.81 | AVPR2 (0.46) | AVPR1AAVPR2OXTR | |
| SCHEMBL5105261 | 0.78 | AVPR2 (0.45) | AVPR1AAVPR2OXTR | |
| SCHEMBL6191112 | 0.78 | AVPR2 (0.45) | AVPR1AAVPR2OXTR | |
| SCHEMBL6207415 | 0.78 | AVPR2 (0.39) | AVPR1AAVPR2OXTRPOLBHSD17B10 | |
| SCHEMBL6208907 | 0.77 | AVPR1A (0.37) | AVPR1AAVPR2OXTRPOLBHSD17B10 | |
| SCHEMBL6068860 | 0.75 | AVPR1A (0.57) | AVPR1AAVPR2OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381607-B1 | NOVEL PYRIDINE- AND CYCLOHEXENYL-COMPRISING PYRROLOBENZODIAZEPINE-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2005-10-26 | — | — | EP | claimed |
| US-6903087-B2 | For prevention and/or suppression of preterm labor, suppression of labor at term prior to caesarean delivery, and for the treatment of dysmenorrhea; useful in enhancing fertility rates | WYETH (US) | 2005-06-07 | — | — | US | claimed |
| EP-1381607-A1 | NOVEL PYRIDINE- AND CYCLOHEXENYL-COMPRISING PYRROLOBENZODIAZEPINE-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-21 | — | — | EP | claimed |
| US-20030055046-A1 | Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | claimed |
| WO-2002083684-A1 | NOVEL PYRIDINE- AND CYCLOHEXENYL-COMPRISING PYRROLOBENZODIAZEPI NE-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | claimed |
| EP-1381607-B1 | NOVEL PYRIDINE- AND CYCLOHEXENYL-COMPRISING PYRROLOBENZODIAZEPINE-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6903087-B2 | For prevention and/or suppression of preterm labor, suppression of labor at term prior to caesarean delivery, and for the treatment of dysmenorrhea; useful in enhancing fertility rates | WYETH (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1381607-A1 | NOVEL PYRIDINE- AND CYCLOHEXENYL-COMPRISING PYRROLOBENZODIAZEPINE-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030055046-A1 | Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | disclosed |
| WO-2002083684-A1 | NOVEL PYRIDINE- AND CYCLOHEXENYL-COMPRISING PYRROLOBENZODIAZEPI NE-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055046-A1 | Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | OXTR, OPRL1, PRLHR | AVPR1A 59/4885AVPR2 74/4885OXTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.